This Plain Language Summary of Publication article (PLSP) from Immunotherapy, the XALOC-1 program combined results from five real-world studies conducted in different countries to assess how well benralizumab works for severe eosinophilic asthma. These retrospective studies analyzed past medical data to evaluate the effectiveness of benralizumab in real-world clinical settings.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme’ and was published in European Respiratory Journal. 

Visit ERS Publications using the link to read the original article.